SCHEMBL377574

SCHEMBL377574

NC(CCCc1ccccc1)C(=O)O

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 2/20 0.73
ALPI P09923 1/20 0.60
PKM P14618 1/20 0.60
PTGS1 P23219 1/20 0.60
XIAP P98170 1/20 0.60
SLC7A5 Q01650 1/20 0.60
LTA4H P09960 1/20 0.53
POLB P06746 1/20 0.53
KMT2A Q03164 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
NOS1 P29475 1/20 0.52
HDAC3 O15379 1/20 0.52
MAPK1 P28482 1/20 0.52
ADRA1A P35348 1/20 0.52
HDAC4 P56524 1/20 0.52
SLC6A3 Q01959 1/20 0.52
HDAC1 Q13547 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HDAC7 Q8WUI4 1/20 0.52
HDAC2 Q92769 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2130589 1.00 GRIK1 (0.73) GRIK1ALPIPKMPTGS1XIAP
SCHEMBL5082998 1.00 GRIK1 (0.73) GRIK1ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL7359673 0.98 GRIK1 (0.71) GRIK1ALPIPKMPTGS1XIAP
Hydrochloric Acid SCHEMBL27975738 0.98 GRIK1 (0.71) GRIK1ALPIPKMPTGS1XIAP
SCHEMBL372365 0.94 GRIK1 (0.66) GRIK1ALPIPKMPTGS1XIAP
SCHEMBL3390123 0.94 GRIK1 (0.66) GRIK1ALPIPKMPTGS1XIAP
SCHEMBL28465699 0.94 GRIK1 (0.66) GRIK1ALPIPKMPTGS1XIAP
SCHEMBL23176817 0.93 GRIK1 (0.64) GRIK1ALPIPKMPTGS1XIAP
SCHEMBL3664379 0.93 GRIK1 (0.64) GRIK1ALPIPKMPTGS1XIAP
SCHEMBL17686506 0.93 GRIK1 (0.64) GRIK1ALPIPKMPTGS1XIAP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 484 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026099897-A1 NOVEL LINKERS AND ITS PREPARATION METHODS THEREOF ZYDUS LIFESCIENCES LIMITED (IN) 2026-05-15 WO claimed
US-20220135622-A1 ANTIBACTERIAL PEPTIDES AND METHODS OF USE GENENTECH, INC. (US) 2022-05-05 US claimed
CN-107592865-B Peptidomimetic compounds for neutralizing influenza viruses 扬森疫苗与预防公司 2022-01-25 CN claimed
EP-3931205-A1 ANTIBACTERIAL PEPTIDES AND METHODS OF USE Genentech, Inc. (US) 2022-01-05 EP claimed
CN-113788877-A Novel insect kinin analogs and application thereof in aphid control 中国农业大学 2021-12-14 CN claimed
CN-113490682-A Antimicrobial peptides and methods of use thereof 豪夫迈·罗氏有限公司 2021-10-08 CN claimed
US-20200399311-A1 NOVEL PEPTIDE BASED PCSK9 VACCINE ZYDUS LIFESCIENCES LIMITED (IN) 2020-12-24 US claimed
US-10738083-B2 Influenza virus neutralizing peptidomimetic compounds JANSSEN VACCINES & PREVENTION B.V. (NL) 2020-08-11 US claimed
EP-3609532-A1 NOVEL PEPTIDE BASED PCSK9 VACCINE Cadila Healthcare Limited (IN) 2020-02-19 EP claimed
CN-110536696-A PCSK9 vaccine based on new peptide CADILA HEALTHCARE LTD 2019-12-03 CN claimed
CN-102405229-A Short-chain peptides as parathyroid hormone (PTH) receptor agonists CADILA HEALTHCARE LTD 2012-04-04 CN claimed
WO-2010128521-A2 SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST CADILA HEALTHCARE LIMITED (IN) 2010-11-11 WO claimed
CN-101400699-A Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions BRISTOL MYERS SQUIBB CO (US) 2009-04-01 CN claimed
EP-1976873-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS Brystol-Myers Squibb Company (US) 2008-10-08 EP claimed
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY 2007-10-11 US claimed
WO-2007082264-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-07-19 WO claimed
WO-2003087036-A1 STEREOSELECTIVE PROCESS FOR THE SYNTHESIS OF (D)-2-AMINO-5-PHENYLPENTANOIC OR ALKYL ESTER THEREOF ELI LILLY AND COMPANY (US) 2003-10-23 WO claimed
US-20030032774-A1 Novel opioid peptides for the treatment of pain ASTRAZENECA AB 2003-02-13 US claimed
EP-1164141-A2 Opioid peptides and their use for treatment of pain AstraZeneca AB (SE) 2001-12-19 EP claimed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070238669-A1 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS GLP1R, GIPR, IAPP GRIK1 1402/4885ALPI 301/4885PKM 2260/4885
US-10738083-B2 Influenza virus neutralizing peptidomimetic compounds ANPEP, NEU1, NGLY1 GRIK1 3250/4885ALPI 2864/4885PKM 3875/4885
US-20030032774-A1 Novel opioid peptides for the treatment of pain OPRL1, OPRK1, OPRM1 GRIK1 291/4885ALPI 4275/4885PKM 2837/4885
US-20200399311-A1 NOVEL PEPTIDE BASED PCSK9 VACCINE PCSK9, PCSK7, PCSK6 GRIK1 3666/4885ALPI 509/4885PKM 1974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.